Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 2.600
-0.020 (-0.76%)
Jul 25, 2025, 5:29 PM CET
Newbury Pharmaceuticals AB Company Description
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market.
The company offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Newbury Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Lars Minor |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 46 12 11 20 |
| Website | newburypharma.com |
Stock Details
| Ticker Symbol | NEWBRY |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | September - August |
| Reporting Currency | SEK |
| ISIN Number | SE0015244884 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lars Minor | Chief Executive Officer |
| Karl Alexius Tiger Karlsson | Founder and Executive Chairman |
| Christoffer Tell | Chief Financial Officer |
| Fredrik Hellqvist | Vice President of Sales and Marketing |